New York Times, 60 Minutes, Senate Republicans Wrong About DEA Schedule I Rules for Kratom-Derived Molecules

On October 28, The New York Times ran a story with the headline “Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying”. Christina Jewett, the author, claimed the government “reversed course” and “decided to allow some levels of the compound”, referring to mitragynine pseudoindoxyl (MP). She claimed the new notice allows for “25 to 500 times the levels currently found on the market” and insisted on Twitter that there was “an advocacy push that led to HHS reversing the ban” of MP.

Wrong.

On Sunday, November 15, 60 Minutes claimed: “HHS changed its recommendation, increasing the amount of 7-hydroxymitragynine (7-OH) allowed in products by 20-fold”.

Wrong.

On Monday, November 16, Senate Judiciary Republicans posted on Twitter that “DEA revised its emergency scheduling order, doubling the threshold for 7-OH and removing MP from Schedule I.” Attached to the Twitter post was a formal letter from Chuck Grassley and other Republican senators addressed to both the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) with similar claims.

Wrong.

All of the claims attempt to create a narrative that anyone who follows this issue would find ridiculous: lobbyists manipulated HHS into allowing stronger 7-OH and MP products to remain on the market. To accept this you would have to have no knowledge of kratom industry disputes in the past year. The well-funded lobbyists in the American Kratom Association (AKA) and Global Kratom Coalition (GKC) have been lobbying IN FAVOR OF 7-OH and MP prohibition for the past few years. The lobbyists and activists in favor of legal and regulated 7-OH (groups like 7-HOPE) have not prevented 7-OH from hurtling toward prohibition.

To better understand the situation, here is some context the above sources neglected to provide: a timeline of the proposed and ongoing scheduling of 7-OH, MP, and other related molecules.

July 29, 2025.

Health and Human Services (HHS) and FDA gave a press conference announcing they were seeking to place 7-OH on the list of Schedule I controlled substances. Several times during the press conference, FDA Commissioner Marty Makary assured the public that leaf kratom would not be part of that recommendation. “We’re not targeting the kratom leaf or ground-up kratom,” he said, adding that 7-OH-dominant products will be delineated from the trace amounts that occur in natural leaf kratom. Only 7-OH that occurs “above a concentration threshold” will be recommended for scheduling, he said. Makary also stated that 7-OH and plain leaf kratom are “night and day in terms of the public health risk.”

May 12, 2026

FDA Commissioner Marty Makary resigns, long before HHS released any notices of intent regarding 7-OH or MP.

The November 15, 2026 60 Minutes segment on kratom claimed “Calley Means, as well as Dr. Marty Makary, former head of the FDA, both told 60 Minutes they recently resigned from their posts in part because of recent changes to kratom policy shaped, as they say, by business interests, rather than public health.” Means resigned on October 22, soon after the October 14 notice of intent changed to allow for trace amounts of MP and 7-OH in kratom leaf.

Again, Makary resigned a month and a half before the first notices of intent to schedule these molecules appeared, let alone changed.

July 1, 2026.

Two Notices of Intent related to kratom alkaloids were filed by the DEA on July 1, 2026. DEA-1570/Federal Register Docket #2026-13580, titled “Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I” intended to ban all 7-OH with an exemption for trace amounts occurring naturally in plain leaf kratom, specifically stating that “This temporary scheduling action does not apply to botanical kratom products that contain naturally occurring 7-OH below the specified threshold.” The Office of the Assistant Secretary for Health (OASH), part of HHS, also released a request for public input on what constitutes a “safe” threshold for 7-OH.

The other notice, #DEA-1571/Federal Register Docket #2026-13581 (referred to below as “Notice 13581”), titled “Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I,” did not allow for trace levels of MP that may occur in natural leaf kratom (the science is undetermined as to whether it does), declaring “Mitragynine pseudoindoxyl, MGM-15, and MGM-16 are synthetic derivatives of the indole alkaloids, mitragynine or 7-hydroxymitragynine, of the Mitragyna speciosa plant.”

7-OH is a metabolite of mitragynine, kratom’s most abundant alkaloid. It can also occur naturally in plain leaf kratom through oxidation. MP is a metabolite of 7-OH.

In a July 1 press release, the American Kratom Association (AKA) agreed with Notice 13581. “MP, MGM-15, and MGM-16 do not occur naturally in the plant. MP is a chemical rearrangement product of 7-OH, while MGM-15 and MGM-16 are synthetic derivatives of 7-OH.”

August 2, 2026

A month and a day after the notices of intent were filed, the AKA seemed to have changed its mind. On Twitter, AKA openly called on comedian Joe Rogan to help stop the ban of “naturally occurring MP”, reposting a 2016 tweet from Rogan regarding the DEA’s intent to schedule kratom that year with this comment: “We’re having this fight again…Notice #13581 bans naturally occurring MP (Mitragynine pseudoindoxyl) under the same ban of Synthetic MGM-15 and MGM-16. We need your help!”

August 26, 2026.

DEA published an order to place MP, MGM-15, and MGM-16 on Schedule I of the federal list of controlled substances for a period of two years. At this time, no threshold amount was announced for naturally occurring trace amounts of MP in kratom leaf.

October 14, 2026.

DEA now appeared to have changed its position on whether MP can occur naturally, announcing a revised version of DEA-1570. This notice still maintains Schedule I status for 7-OH and MP, but allows for very trace threshold amounts possibly occurring in leaf kratom. DEA states explicitly that MP’s previous Schedule I status remains in effect: “The August 26, 2026 temporary order placing mitragynine pseudoindoxyl in schedule I of the CSA without a threshold remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first.“

DEA explicitly laid out the new threshold amounts:

The substances [7-hydroxymitragynine] and [mitragynine pseudoindoxyl] be controlled in schedule I [pursuant to 21 U.S.C. 811(h)] when either substance alone, or their combined amount if both present, is:

(A) Above a specified threshold concentration, that is, greater than 1 mg per gram (for solid powders, encapsulated material, or other solid forms) or greater than 1 mg per milliliter (for liquid preparations), OR

(B) The mass of mitragynine present divided by the mass of [7-hydroxymitragynine], or [mitragynine pseudoindoxyl], or the combined amount of [7-hydroxymitragynine] and [mitragynine pseudoindoxyl] if both present, is less than 100.

Conclusion.

New York Times, 60 Minutes, and Senate Republicans all seemed to have neglected to read, or deliberately ignored, section B in the quote above. The 100:1 rule means that a product must contain at least 100 parts mitragynine for every one part of 7-OH and MP combined to avoid triggering this particular scheduling provision. If the ratio falls below 100:1, the product can be placed in Schedule I regardless of whether its 7-OH or MP concentration exceeds the separate 1 mg/g or 1 mg/mL limits.

The 100:1 rule certainly makes all concentrated 7-OH and MP products illegal under Schedule I of the Controlled Substances Act, but allows for leaf kratom and kratom extracts to remain legal. It would be ridiculous for kratom industry lobbyists to lobby in favor of strong 7-OH and MP products when the entire scheduling move by HHS, FDA, and DEA was a result of kratom industry lobbying in favor of 7-OH and MP prohibition in the first place.

Jewett’s claim in the New York Times and on Twitter that HHS reversed the ban is simply untrue. A Notice of Intent does not reverse the ban. Even if the updated notice becomes an updated order, MP will still be a Schedule I controlled substance. As far as the claim that the rules laid out in the new notice will allow MP to occur at “25 to 500 times the levels currently found on the market”, that would on be possible with MP if the 100:1 rule is disregarded. This rule was left out of the New York Times October 28 article.

60 Minutes’ claim that “HHS changed its recommendation, increasing the amount of 7-hydroxymitragynine (7-OH) allowed in products by 20-fold” is wrong. The original recommendation included a 0.05% concentration limit and a separate 1 mg-per-product threshold. The revised recommendation replaces those criteria with a limit of 1 mg per gram for solids and 1 mg per milliliter for liquids, while also adding mitragynine pseudoindoxyl (MP) and a separate 100:1 mitragynine-to-7-OH/MP ratio test. Therefore, the increase is at most twofold, depending on the product and whether it passes the 100:1 ratio test.

Senate Republicans claimed, “DEA revised its emergency scheduling order, doubling the threshold for 7-OH and removing MP from Schedule I.” Again, whether the threshold has doubled depends on the 100:1 ratio test, but at least Senate Republicans didn’t claim it had increased 20-fold. MP is not now and will not be removed from Schedule I. MP has not been removed from Schedule I and will remain there if this notice becomes an order.

Republican senators Chuck Grassley, Susan Collins, and Mike Lee penned an October 7 letter urging the DEA and FDA to ban all kratom, and therefore may be wholly unconcerned with reading the details of the rules governing allowable thresholds for certain molecules.

Journalists have no excuse.

Leave a Comment

Your email address will not be published. Required fields are marked *